期刊文献+

α1,2-岩藻糖转移酶基因转导对人卵巢癌细胞RMG-I p38MAPK信号通路介导的凋亡的影响 被引量:3

The Effect of α1,2-Fucosyl Transferase Gene Transfection on p38MAPK Signaling Pathway-mediated Apoptosis of Ovarian Carcinoma RMG-I Cells
下载PDF
导出
摘要 以α1,2-岩藻糖转移酶基因转染前后卵巢癌细胞RMG-I、RMG-I-H为细胞模型,用细胞免疫荧光方法检测转染前后细胞p38MAPK和p-p38MAPK的细胞内定位,RT-PCR和Western blot方法从mRNA和蛋白质两个水平检测转染前后细胞p38MAPK表达的变化;以兔抗人IgG抗体处理组为对照,分别利用RT-PCR和Western blot方法检测Lewisy单克隆抗体处理前后RMG-I-H细胞p38MAPK mRNA和蛋白质表达水平的变化;以0.1%DMSO为对照,用流式细胞仪(FCM)检测p38MAPK特异性抑制剂SB203580处理后RMG-I-H凋亡比率的变化,并利用RT-PCR和Western blot方法检测caspase-3的mRNA和蛋白质水平的变化;用RT-PCR方法检测卡铂和SB203580处理后p38MAPK及caspase-3表达的变化.结果表明,RMG-I与RMG-I-H的p38MAPK蛋白主要定位在细胞质,p-p38MAPK蛋白定位在细胞核,转染后p38MAPK的mRNA水平明显高于转染前(P<0.05);Lewisy单克隆抗体处理后RMG-I-H细胞p38MAPK mRNA水平降低(P<0.05),不同浓度SB203580(0.1mmol/L,1mmol/L,10mmol/L)作用下RMG-I-H细胞的凋亡率分别为(15.927±0.861)%、(18.187±0.481)%及(33.565±0.912)%,明显高于空白组和对照组(P<0.05),SB203580处理后caspase-3的mRNA和蛋白质水平均明显高于空白组和对照组(P<0.05),卡铂处理后p38MAPK及caspase-3 mRNA水平均增加,SB203580处理后,caspase-3mRNA水平增加.说明Lewisy抗原介导的卵巢癌细胞凋亡与p38MAPK信号通路有关,可能通过p38MAPK信号通路抑制卵巢癌细胞凋亡,引起耐药性. To study the effect of α1,2-fucosyltransferase gene transfection on p38MAPK signaling pathwaymediated apoptosis in ovarian carcinoma RMG-I cells.The localization of p38MAPK and p-p38MAPK was detected by immunofluorescence in RMG-I and RMG-I-H cells.The expression of p38MAPK and p-p38MAPK was analyzed by RT-PCR and Western blot,respectively.For inhibition assay,anti-Lewis y antibody was used to assess the change of p38MAPK of mRNA level in RMG-I-H cells by RT-PCR and Western blot.Using 0.1% DMSO as control,the apoptosis rate was detected by flow cytometry(FCM) in SB203580 treated RMG-I-H cells.Simultaneously,the expression of p38MAPK and caspase-3 was analyzed by RT-PCR and Western blot.Further more,the expression of p38MAPK and caspase-3 by RT-PCR after Carboplatin and/or SB203580 treatment were studied.Results showed that immunofluorescence staining of p38MAPK and p-p38MAPK in RMG-I and RMG-I-H cells showed cytoplasmic localization and nuclear localization,respectively,and the level of p-p38MAPK mRNA in RMG-I-H cells is significantly higher than that in RMG-I cells(P 0.05),while the expression of p-p38MAPK mRNA decreased after anti-Lewis y antibody treatment(P 0.05).FCM showed that the apoptosis rate increased in SB203580 treated RMG-I-H cells(P 0.05).The mRNA level of p38MAPK and caspase-3 increased by treatment with Carboplatin.The mRNA level of caspase-3 also elevated by treatment with SB203580.In conclusion,high expression of Lewis y inhibits apoptosis in ovarian cancer cells,probably due to involvement of Lewis y in regulating p38MAPK signaling pathway,thereby causing drug resistance.
出处 《生物化学与生物物理进展》 SCIE CAS CSCD 北大核心 2010年第2期175-183,共9页 Progress In Biochemistry and Biophysics
基金 国家自然科学基金(30170980 30571958 30872757) 辽宁省教育厅攻关项目(20121268) 辽宁省自然基金(20052107) 教育部博士点基金(20070159023) 辽宁省教育厅重点实验室项目(2008S247) 盛京自由研究者计划(200807)资助项目~~
关键词 卵巢癌 Lewisy抗原 P38MAPK 凋亡 ovarian cancer Lewis y antigen p38MAPK apoptosis
  • 相关文献

参考文献14

二级参考文献83

  • 1林蓓,齐藤真木子,岩森正男.小鼠α1,2岩藻糖基转移酶基因的克隆及表达[J].实验生物学报,2005,38(6):536-544. 被引量:1
  • 2刘涛,孔垂泽,毕建斌,刘戈飞.蛋白激酶C抑制剂逆转肾癌多药耐药机制的探讨[J].中华肿瘤杂志,2006,28(2):92-95. 被引量:9
  • 3张甦琳,孔维佳.喉癌体外药物敏感实验对化疗指导性的研究[J].临床耳鼻咽喉科杂志,2006,20(15):711-713. 被引量:3
  • 4Liu F, Qi HL & Chen HL, Regulation of differentiationand prolifertion-inducers on Lewis antigens, alpha-fucosyhransferase and metastatic potential in hepatocarcinoma cells. Br J Cancer, 2001 ; 84(11) : 1 556-1 563.
  • 5Inufusa H, Adachi T, Kiyokawa T, Nakatani Y, Wakano T, Nakamura M, Okuno K, Shiozaki H, Yamamoto S, Suzuki M, Ando O, Kurimoto M, Miyake M & Yasutomi M, Ley glycolipid-recognizing monoclonal antibody inhibits procoagulant activity and metastasis of human adenocarcinoma. Int J Oncol, 2001, 19(5) : 941-946.
  • 6Scott AM, Geleick D, Rubira M, Clarke K, Nice EC, Smyth FE, Stockert E, Richards EC, Carr FL, Harris WJ, Armour KL, Rood J, Kypridis A, Kronina V, Murphy R, Lee Fr, Liu Z, Kitamura K, Rittter G, Laughton K, Hoffman E, Burgess AW & Old I J, Construction, production, and characterization of humanized anti-Lewis y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Research, 2000, 60(15): 3 254-3 261.
  • 7Sabbatini PJ, Kudryashov V, Ragupathi G, Danishefsky S J, Livingston PO, Bornmann W, spassova M, Zatorski A, Spriggs D, Aghajanian C, Soignet S, Pevton M, O'Flaherty CC, Curtin J & Lloyd KO, Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer, 2000, 87(1): 79-85.
  • 8Halloran MM, Carley WW, Polverini PJ, Haskell C J, Phan S, Anderson B J, Woods JM, Campbell PL, Volin MV, Backer AE & Koch AE, Ley/H: an endothelial-selective, cytokine-inducible, angiogenic mediator. J Immunol, 2000, 164(9): 4 868-4 877.
  • 9Basu A, Murthy U, Rodeck U, Herlyn M, Mattes L & Das M, Presence of tumor-associated antigens in epidermal growth factor receptors from different human carcinomas. CancerRes, 1987, 47(10): 2 531-2 536.
  • 10Federici MF, Kudryashov V, Saigo PE, Finstad CL & Llovd KO, Selection of carbohydrate antigens in human epithelial ovarian cancers as targets for immunotherapy: serous and mucinous tumors exhibit distinctive patterns of expression. Int J Cancer, 1999, 81(2) : 193-198.

共引文献16

同被引文献22

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部